Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance |
| |
| Authors: | Michael W. Jann Stephen R. Saklad Larry Ereshefsky Ann L. Richards Charles A. Harrington Chester M. Davis |
| |
| Affiliation: | (1) College of Pharmacy, The University of Texas at Austin, USA;(2) Department of Pharmacology, The University of Texas Health Science Center at San Antonio, USA;(3) Department of Psychiatry, The University of Texas Health Science Center at San Antonio, USA;(4) Department of Psychiatry, University of Texas Mental Science Institute, USA;(5) San Antonio State School, USA;(6) San Antonio State Hospital, 78284 San Antonio, Texas, USA;(7) Clinical Pharmacy Program, The University of Texas Health Science Center, 7703 Floyd Curl Drive, 78284 San Antonio, Texas, USA |
| |
| Abstract: | Plasma concentrations of haloperidol and its reduced metabolite (reduced haloperidol) were investigated in cigarette smokers (N=23) and nonsmokers (N=27). Steady-state plasma concentrations were obtained 12 h post bedtime dose. Haloperidol and reduced haloperidol concentrations were determined by RIA. Reduced haloperidol was separated by selective succinylation and liquid chromatography. Patients were clinically assessed with the Clinical Global Impression Scale (CGIS). Smokers had significantly lower haloperidol and reduced haloperidol plasma concentrations than nonsmokers (P<0.01, P<0.05). Clearance of haloperidol was significantly greater in smokers compared to nonsmokers (P=0.0052). CGIS assessments did not show significant differences between smokers and non-smokers. Plasma concentrations should be carefully monitored when patients either start or stop smoking.Presented at the IV World Congress of Biological Psychiatry, Philadelphia, PA, September 8–13, 1985 |
| |
| Keywords: | Smoking Haloperidol Reduced haloperidol Plasma concentrations Clearance |
| 本文献已被 SpringerLink 等数据库收录！ |
|
